T-DXd
Gastric Cancer
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: Exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial
Shitara K, Bang Y-J, Iwasa S, et al.
Nat Med. 2024;30(7):1933-1942. doi: 10.1038/s41591-024-02992-x.
Dato-DXd
Breast Cancer
Datopotamab deruxtecan in advanced or metastatic HR+/HER2- and triple-negative breast cancer: Results from the phase I TROPION-PanTumor01 study
Bardia A, Krop IE, Kogawa T, et al.
J Clin Oncol. 2024;42(19):2281-2294. doi: 10.1200/JCO.23.01909. Epub 2024 Apr 2
T-DXd
Breast Cancer Other/Multi
Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: Analysis of the phase Ib DS8201-A-U105 study
Hamilton E, Galsky MD, Ochsenreither S, et al.
Clin Cancer Res. 2024;30(24):5548-5558. doi: 10.1158/1078-0432.CCR-24-1513
Quizartinib
Other/Multi
A study to learn how well quizartinib with chemotherapy works and how safe it is in people with acute myeloid leukemia that is FLT3-ITD-positive: A plain language summary of the QuANTUM-First study
Erba HP
Future Oncol. 2024:1-15. doi: 10.1080/14796694.2024.2422261.
HER3-DXd
Tumor-agnostic
Prevalence of HER3 expression in pancreatic cancer patients treated with systemic chemotherapy
Satake T, Morizane C, Okada M, et al.
Cancer Med. 2024;13(23):e70474. doi: 10.1002/cam4.70474.
Other/Multi
Other/Multi
Decoding clinical trial jargon: Helping people understand how safety and quality of life are assessed in cancer trials
Burkholder J, Burkholder A, DeCotiis G, FitzGibbon H, Mehta P.
Future Oncol. 2025;21(1):5-10. doi: 10.1080/14796694.2024.2422808.
Quizartinib
Other/Multi
Population pharmacokinetic analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia
Vaddady P, Glatard A, Smania G, et al.
Clin Transl Sci. 2024;17(12):e70074. doi: 10.1111/cts.70074.
T-DXd
Colorectal Cancer
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: Biomarker analyses of DESTINY-CRC01
Siena S, Raghav K, Masuishi T, et al.
Nat Commun. 2024;15(1):10213. doi: 10.1038/s41467-024-53223-3.
Dato-DXd
Breast Cancer
Anti-tumor activity and biomarker analysis for TROP2 antibody-drug conjugate datopotamab deruxtecan in patient-derived breast cancer xenograft models
Meric-Bernstam F, Yuca E, Evans KW, et al.
Clin Cancer Res. 2024. doi: 10.1158/1078-0432.CCR-24-1948.
Edoxaban
Cardiovascular - VTE
Population pharmacokinetics and pharmacodynamics of edoxaban in pediatric patients
Zou P, Atluri A, Chang P, et al.
CPT Pharmacometrics Syst Pharmacol. 2025;14(1):118-129. doi: 10.1002/psp4.13248.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26